Strongest evidence
- Reduced C-reactive protein (CRP): All 4 studies showed beneficial effects with a moderate effect size. Doses ranged from 500 mg/day to 3 g/day, studied primarily in adults with migraine, sepsis, or impaired glucose tolerance.
- Reduced triglycerides: 4 of 5 studies reported small beneficial effects. The most consistent dose was 2-3 g/day, and the strongest evidence comes from a large RCT in women with PCOS.
- Reduced LDL cholesterol: 3 of 4 studies showed small reductions, with the largest meta-analysis in type 2 diabetes (n=2041) finding a small decrease.
- Reduced BMI: 3 of 5 studies found small benefits, typically at doses of 1-4 g/day in adults with type 2 diabetes or on hemodialysis.
Mixed or weaker evidence
- Reduced fasting blood glucose: All 3 studies reported small beneficial effects, but the evidence base is small (n=3 studies) and confined to clinical populations.
- Reduced body weight: 3 of 3 studies showed benefit, but effect sizes ranged from small to large and the evidence strength is low due to few studies and wide dose ranges (150-4000 mg/day).
- Reduced cholesterol (total): 2 of 3 studies found benefit, but results were inconsistent across populations (type 2 diabetes vs. PCOS).
- Reduced malondialdehyde (oxidative stress marker): 2 of 3 studies showed benefit, but evidence is preliminary and one study in critically ill patients found no effect.
- Reduced systolic blood pressure: All 3 studies found neutral effects — no significant reduction.
- Reduced mortality rate: Only 1 of 3 studies found benefit (in septic patients); the two larger meta-analyses found no significant effect on mortality.
Effective dose patterns
Most outcomes with positive findings used doses between 1-3 g/day. Triglyceride reduction was most studied at 2-3 g/day, while CRP reduction spanned a wider range (500 mg to 3 g/day). For weight-related outcomes, doses varied widely (150-4000 mg/day), making a precise range difficult to identify. Many studies did not report duration precisely, but effects were typically seen after 6-8 weeks.
Population insights
The majority of positive studies were conducted in clinical populations — adults with type 2 diabetes, PCOS, or impaired glucose tolerance. Hemodialysis patients were included in several analyses but sometimes showed neutral results (e.g., for triglycerides and VLDL). The strongest effect on CRP was seen in adults with migraine or sepsis. Effects on mortality were studied only in critically ill septic patients, not in general populations.
Notable caveats
- Publication bias is flagged across nearly all outcomes — null results may be underrepresented in the published literature.
- Most evidence strengths are moderate at best; only a few outcomes have low strength due to small numbers of studies.
- The evidence base is small for many outcomes (3-5 studies per synthesis), so conclusions should be considered preliminary.
- Studies used different L-carnitine forms (L-carnitine, L-carnitine-tartrate) and durations, making direct comparisons difficult.
- Results from critically ill populations (sepsis, short 7-day treatment) may not generalize to healthy adults or long-term use.